Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Current Quarter	$-1.2	Next Quarter	$-1.33
Current Year	$-9.27	Next Year	$-4.52
QoQ Growth	-10.8%	YoY Growth	+51.2%
3Y EPS CAGR	+78.8%	Target Price	$47.00
Consensus	Buy	Upside	+1198.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLRB	$3.62	-4.23%	50.42K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CLRB	$3.62	-4.2%	50.42K
3
4
5
6

CLRB

CLRB

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Cellectar Biosciences Inc. Data in Excel

Get Cellectar Biosciences Inc. Data in Excel